reports
Lantheus to Host First Quarter 2024 Earnings Conference Call and Webca...
Lantheus to Host First Quarter 2024 Earnings Conference Call and Webcast on May 2, 2024, at 8:00 a.m. Eastern Time BEDFORD, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, May 2, 2024, to discuss its financial and operating results for the first quarter of 2024. To access the conference call or webcast, participants should register online at . To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. A replay will be avai...
Lantheus to Present at the Leerink Partners Global Biopharma Conferenc...
Lantheus to Present at the Leerink Partners Global Biopharma Conference 2024 BEDFORD, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Paul Blanchfield, President, will present at the Leerink Partners Global Biopharma Conference 2024 at 9:20 a.m. ET on Tuesday, March 12. To access a live webcast of the presentation, please visit the section of the Company’s website at . A repla...
Lantheus Announces the FDA Approval of DEFINITY® (Perflutren Lipid Mic...
Lantheus Announces the FDA Approval of DEFINITY® (Perflutren Lipid Microsphere) for Pediatric Patients DEFINITY is the #1 utilized ultrasound enhancing agent in the U.S. for patients with suboptimal echocardiograms BEDFORD, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow® disease to deliver better patient outcomes, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA)...
Lantheus Announces Promotion of Amanda Morgan to Chief Commercial Offi...
Lantheus Announces Promotion of Amanda Morgan to Chief Commercial Officer BEDFORD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the promotion of Amanda Morgan to Chief Commercial Officer and her elevation to be a member of the company’s Executive Team, effective March 25, 2024. In her role, Ms. Morgan will continue to lead the Company’s commercial strategy and activities, incl...
Lantheus to Present at the TD Cowen 44th Annual Health Care Conference
Lantheus to Present at the TD Cowen 44th Annual Health Care Conference BEDFORD, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Paul Blanchfield, President, will present at the TD Cowen 44th Annual Health Care Conference at 10:30 a.m. ET on Monday, March 4. To access a live webcast of the presentation, please visit the section of the Company’s website at . A replay of the webca...
Lantheus Reports Fourth Quarter and Full Year 2023 Financial Results
Lantheus Reports Fourth Quarter and Full Year 2023 Financial Results Worldwide revenue of $354.0 million and $1.3 billion for the fourth quarter and full year 2023GAAP net income of $103.4 million and $326.7 million for the fourth quarter and full year 2023GAAP fully diluted net income per share of $1.47 and $4.65 for the fourth quarter and full year 2023 Adjusted fully diluted net income per share of $1.75 and $6.23 for the fourth quarter and full year 2023Net cash provided by operating activities was $112.3 million and $305.3 million for the fourth quarter and full year 2023 and free cash...
Lantheus Announces Collaboration to Provide Novel Tau Imaging Agent fo...
Lantheus Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging Lantheus to supply MK-6240, an investigational F18-labeled PET imaging agent that targets tau tangles BEDFORD, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced a collaboration agreement with a National Institute on Aging (NIA)-sponso...
Lantheus to Host Fourth Quarter and Full Year 2023 Earnings Conference...
Lantheus to Host Fourth Quarter and Full Year 2023 Earnings Conference Call and Webcast on February 22, 2024, at 8:00 a.m. Eastern Time BEDFORD, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, February 22, 2024, to discuss its financial and operating results for the fourth quarter and full year of 2023. To access the conference call or webcast, participants should register online at . To avoid delays, we encourage participants to register fifteen minutes ahead of the ...
- Dave Nicoski
- Ross LaDuke
Vermilion Short Shots: Technically Vulnerable Stocks
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
NFG NATIONAL FUEL GAS COMPANY
MOS MOSAIC COMPANY
MGPI MGP INGREDIENTS INC.
DLY LYONDELLBASELL INDUSTRIES NV
LNTH LANTHEUS HOLDINGS INC
KMB KIMBERLY-CLARK CORPORATION
HRL HORMEL FOODS CORPORATION
HAE HAEMONETICS CORPORATION
GPRE GREEN PLAINS INC.
FNV. FRANCO-NEVADA CORPORATION
DVN DEVON ENERGY CORPORATION
CVE CENOVUS ENERGY INC.
CNMD CONMED CORPORATION
APD AIR PRODUCTS AND CHEMICALS INC.
AIR AAR CORP.
MAT MATTEL INC.
MED MEDIFAST INC.
BKR BAKER HUGHES COMPANY CLASS A
SSRM SSR MINING INC
DD DUPONT DE NEMOURS INC.
GNMSY GENMAB A/S
XPEV XPENG INC. ADR SPONSORED CLASS A
COCO THE VITA COCO CO INC
SGML SIGMA LITHIUM CORP
KXI. ISHARES S&P GLOBAL CONSUMER STAPLES SECTOR INDEX FUND
DO DIAMOND OFFSHORE DRILLING INC.
SHEL SHELL PLC
BG BUNGE LIMITED
Lantheus Announces CEO Succession Plan
Lantheus Announces CEO Succession Plan Lantheus Board Member and Pharmaceutical Industry Veteran Brian Markison Appointed Lantheus Chief Executive Officer, Effective March 1, 2024 Mary Anne Heino to Retire as Chief Executive Officer and Become Chair of the Board of Directors BEDFORD, Mass., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that the Company has appointed Brian Markison,...
Lantheus Announces Acceptance of its First-to-File ANDA for Generic LU...
Lantheus Announces Acceptance of its First-to-File ANDA for Generic LUTATHERA® (Lutetium Lu 177 Dotatate) BEDFORD, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that its Abbreviated New Drug Application (ANDA) for Lutetium Lu 177 Dotatate (177Lu-PNT2003), a generic version of LUTATHERA® (lutetium Lu 177 dotatate), has been accepted for filing by the U.S. Food a...
Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic A...
Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics Option to license Perspective Therapeutics’ Pb212-VMT-α-NET asset Co-development rights for certain Pb212-based alpha therapies for prostate cancer Equity investment of up to 19.9% in Perspective Therapeutics Perspective Therapeutics intends to acquire Somerset, NJ radiopharmaceutical manufacturing facility BEDFORD, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus) (NASDAQ: LNTH) today announced it has entered into multiple strategic agreements with ...
Lantheus Reports Preliminary Fiscal Year 2023 Revenue
Lantheus Reports Preliminary Fiscal Year 2023 Revenue Full year 2023 worldwide revenue expected to be in the range of $1.295 – 1.297 billion, a 38 - 39% increase over the prior year including a $15 million RELISTOR milestone achievement Full year 2023 PYLARIFY revenue expected to be in the range of $851 - 853 million, pending final partner reconciliation, an increase of 61 - 62% over the prior year Full year 2023 DEFINITY revenue expected to be approximately $279 million, a 14% increase over the prior year BEDFORD, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the C...
Lantheus to Present at the 42nd Annual J.P. Morgan Healthcare Conferen...
Lantheus to Present at the 42nd Annual J.P. Morgan Healthcare Conference BEDFORD, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Mary Anne Heino, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference at 11:15 a.m. PST on Wednesday, January 10. To access a live webcast of the presentation, please visit the Investors section of the Company’s w...
Lantheus and POINT Biopharma Announce Positive Topline Results from Pi...
Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer Phase 3 SPLASH study of 177Lu-PNT2002 demonstrated statistically significant improvement in radiographic progression-free survival (rPFS) BEDFORD, Mass., and INDIANAPOLIS, Dec. 18, 2023 (GLOBE NEWSWIRE) -- December 18, 2023 – Lantheus Holdings, Inc. (Lantheus) (NASDAQ: LNTH) and POINT Biopharma Global Inc. (POINT) (NASDAQ: PNT) today announced statistically significant topline results from the pivotal Phase 3 SPLASH study evaluating the efficacy ...
Lantheus to Present at the Jefferies London Healthcare Conference
Lantheus to Present at the Jefferies London Healthcare Conference BEDFORD, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes,, today announced Paul Blanchfield, President, and Bob Marshall, Chief Financial Officer and Treasurer, will present at the Jefferies London Healthcare Conference at 8:00 a.m. GMT (3 a.m. EST) on Wednesday, November 15. To access a live webcast of the presentation, please vi...
Lantheus Reports Third Quarter 2023 Financial Results
Lantheus Reports Third Quarter 2023 Financial Results Worldwide revenue of $319.9 million for the third quarter 2023, representing an increase of 33.7% from the prior year periodGAAP net income of $132.0 million for the third quarter 2023, compared to GAAP net income of $61.2 million in the prior year periodGAAP fully diluted net income per share of $1.88 for the third quarter 2023, compared to GAAP fully diluted net income per share of $0.86 in the prior year period; adjusted fully diluted net income per share of $1.47 for the third quarter 2023, compared to adjusted fully diluted net inco...
Lantheus to Host Third Quarter 2023 Earnings Conference Call and Webca...
Lantheus to Host Third Quarter 2023 Earnings Conference Call and Webcast on November 2, 2023, at 8:00 a.m. Eastern Time BEDFORD, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, November 2, 2023, to discuss its financial and operating results for the third quarter of 2023. To access the conference call or webcast, participants should register online at . To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. A replay wil...
Lantheus Announces Top Rated Oral Presentation Featuring PYLARIFY AI™ ...
Lantheus Announces Top Rated Oral Presentation Featuring PYLARIFY AI™ at the 2023 European Association of Nuclear Medicine (EANM) Annual Meeting BEDFORD, Mass., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, announced PYLARIFY AI data will be presented at the upcoming 2023 European Association of Nuclear Medicine (EANM) Annual Meeting, which will be held September 9...
Lantheus to Present at the Wells Fargo Healthcare Conference
Lantheus to Present at the Wells Fargo Healthcare Conference BEDFORD, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, today announced Paul Blanchfield, President, and Bob Marshall, Chief Financial Officer and Treasurer, will present at the Wells Fargo Healthcare Conference at 9:30 a.m. ET on Thursday, September 7. To access a live webcast of the presentation, p...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.